Tazarotene Excels Across BMI Categories

April 14, 2021

Data from trials show tazarotene 0.045% lotion is an effective treatment for moderate to severe facial acne and improves acne-related QOL in patients across BMI categories.

Malignancy Risk Low in Secukinumab Treatment
Study Confirms Safety Profile of Baricitinib Dose for Atopic Dermatitis
Solving Pierced Earring Challenges
The Mainstream Patient: April 12, 2021